AVRO - Avrobio: 3 Promising Phase 1/2 Therapeutics $220M In Cash And 2021 Catalysts
- AVROBIO, Inc. is a clinical-stage gene therapy biotechnology company focused on developing single-dose curative ex-vivo lentiviral-based gene therapies for rare diseases.
- AVROBIO is developing a pipeline of six gene-therapeutics covering Fabry's disease (AVR-RD-01), Gaucher Type 1 (AVR-RD-02), Cystinosis (AVR-RD-04), Hunter syndrome (AVR-RD-05), Gaucher Type 3 (AVR-RD-06), and Pompe disease (AVR-RD-03), a $4.6B combined-market.
- AVROBIO is a non-revenue-producing, early-stage biotech with a cash basis of $220M (9m 2020) and expectations for 2022 and 2025 revenues of $14M and $228M, respectively.
- AVROBIO's next major catalyst is the Q1 2021 AVR-RD-02's (Gaucher's Disease) presentation of six-month data at the WORLDSymposium.
- In summary, the author projects AVROBIO, Inc. as a "buy" at a five-year price target of $68 (+383% upside | 29% CAGR).
For further details see:
Avrobio: 3 Promising Phase 1/2 Therapeutics, $220M In Cash, And 2021 Catalysts